121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Empowered Funds LLC

Empowered Funds LLC bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 121,446 shares of the specialty pharmaceutical company's stock, valued at approximately $4,693,000. Empowered Funds LLC owned about 0.38% of Collegium Pharmaceutical as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COLL. Gladius Capital Management LP purchased a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $32,000. nVerses Capital LLC raised its holdings in Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC lifted its position in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 792 shares during the last quarter. CWM LLC boosted its stake in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after buying an additional 736 shares during the period. Finally, Sheaff Brock Investment Advisors LLC bought a new position in Collegium Pharmaceutical during the first quarter valued at $204,000.

Insiders Place Their Bets

In other news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on COLL shares. Needham & Company LLC restated a "hold" rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Truist Financial upped their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Piper Sandler reissued a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. Finally, HC Wainwright lifted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $42.60.

Collegium Pharmaceutical Trading Down 1.2 %

COLL traded down $0.36 during trading on Monday, hitting $29.22. 562,020 shares of the stock were exchanged, compared to its average volume of 445,685. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The firm has a 50 day simple moving average of $36.36 and a 200 day simple moving average of $35.00. The firm has a market cap of $942.35 million, a price-to-earnings ratio of 12.65 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 1 year low of $25.13 and a 1 year high of $42.29.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.